UROV has been the subject of several other research reports. HC Wainwright raised their price target on shares of Urovant Sciences from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. Zacks Investment Research lowered shares of Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $22.69.
Shares of UROV stock traded down $0.14 during trading hours on Tuesday, hitting $12.85. 868 shares of the company were exchanged, compared to its average volume of 62,889. The firm has a fifty day simple moving average of $13.26 and a 200 day simple moving average of $10.09. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 1.83. Urovant Sciences has a 52-week low of $6.45 and a 52-week high of $15.98. The stock has a market capitalization of $392.92 million, a price-to-earnings ratio of -3.03 and a beta of 1.97.
A number of institutional investors have recently added to or reduced their stakes in UROV. Marshall Wace North America L.P. purchased a new position in Urovant Sciences in the 1st quarter valued at approximately $49,000. Northern Trust Corp grew its stake in Urovant Sciences by 55.8% in the 2nd quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock valued at $136,000 after buying an additional 6,144 shares in the last quarter. First Trust Advisors LP purchased a new position in Urovant Sciences in the 3rd quarter valued at approximately $163,000. Marshall Wace LLP purchased a new position in Urovant Sciences in the 1st quarter valued at approximately $325,000. Finally, LVW Advisors LLC purchased a new position in Urovant Sciences in the 3rd quarter valued at approximately $372,000. Institutional investors and hedge funds own 22.37% of the company’s stock.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: How prevalent are 12b-1 fees?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.